Literature DB >> 2162022

Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis.

C G Parsons1, A Członkowski, C Stein, A Herz.   

Abstract

This study investigated the involvement of endogenous opioid peptides in mediating cold water swim (CWS) stress-induced antinociception (SIA) in rats with unilateral hind paw inflammation induced by Freund's complete adjuvant (FCA). Following 0.5, 1 and 2 min of CWS, there was a duration-dependent elevation of paw pressure threshold (PPT) in both inflamed and non-inflamed paws which was maximal immediately after CWS and returned to control values within 15 min. The antinociception elicited in the inflamed paw was significantly greater than that elicited in the non-inflamed paw. The antinociception induced by a 1 min CWS was dose dependently antagonized by tertiary naloxone (0.125-1 mg/kg s.c.) and completely reversed by tertiary naltrexone (0.5 mg/kg). Quaternary naltrexone (5-40 mg/kg s.c.) was similarly effective in reversing the elevation of inflamed PPT induced by a 1 min CWS stress. In contrast, similar doses of quaternary naltrexone had no effect against centrally mediated morphine antinociception in non-inoculated rats. Adrenalectomy was without effect on the pattern of SIA seen in FCA-treated rats. Surgical hypophysectomy completely abolished the differential antinociception induced by 0.5 and 1 min durations of CWS but had little effect on that following 2 min of CWS stress. Inhibition of hypophysial corticotrophic cell secretion with dexamethasone (300 micrograms/kg) injected s.c. 120 min prior to CWS completely abolished the differential SIA at all durations of CWS tested. beta-Endorphin 12.5 micrograms/kg administered i.v. in non-stressed rats also caused a greater elevation of PPT in inflamed than in non-inflamed paws. This effect was not reversed by concomitant i.v. administration of (-) tertiary naloxone 5 mg/kg or quaternary naltrexone 20 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162022     DOI: 10.1016/0304-3959(90)91112-v

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  [Peripheral opioid receptors and their role in postoperative pain management.].

Authors:  C Stein
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

2.  Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation.

Authors:  C Stein; A H Hassan; R Przewłocki; C Gramsch; K Peter; A Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration.

Authors:  B S Silbert; A W Lipkowski; M S Cepeda; S K Szyfelbein; P F Osgood; D B Carr
Journal:  Agents Actions       Date:  1991-07

4.  Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat.

Authors:  P Honoré; J Buritova; J M Besson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice.

Authors:  Daniel J Bruce; Cristina D Peterson; Kelley F Kitto; Eyup Akgün; Sophia Lazzaroni; Phillip S Portoghese; Carolyn A Fairbanks; George L Wilcox
Journal:  Anesthesiology       Date:  2019-09       Impact factor: 7.892

6.  Effect of Rhizoma Paridis saponin on the pain behavior in a mouse model of cancer pain.

Authors:  Genbei Wang; Yuanxue Liu; Yu Wang; Wenyuan Gao
Journal:  RSC Adv       Date:  2018-05-09       Impact factor: 4.036

7.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.